EMEA-003519-PIP01-23
Submitted by Anonymous (not verified) on 21 March 2025 - 15:17
EMEA-003519-PIP01-23
EMEA-003520-PIP01-23
Submitted by Anonymous (not verified) on 21 March 2025 - 15:16
EMEA-003520-PIP01-23
EMEA-003541-PIP01-23
Submitted by Anonymous (not verified) on 21 March 2025 - 15:15
EMEA-003541-PIP01-23
Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Date of authorisation: 20/11/2018, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 21 March 2025 - 15:05
Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Date of authorisation: 20/11/2018, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 21 March 2025 - 15:00
Human medicines European public assessment report (EPAR): Veoza, fezolinetant, Date of authorisation: 07/12/2023, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Date of authorisation: 16/01/2020, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 21 March 2025 - 14:13
Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Date of authorisation: 16/01/2020, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 21 March 2025 - 14:02
Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 8, Status: Authorised
Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 March 2025, 11:00 (CET) to 6 March 2025, 11:30 (CET)
Submitted by Anonymous (not verified) on 21 March 2025 - 13:33
Q&A clinic on web-based electronic Application Form (eAF) functionalities for CAPs and non-CAPs variations, Online, European Medicines Agency, Amsterdam, the Netherlands, from 6 March 2025, 11:00 (CET) to 6 March 2025, 11:30 (CET)
Orphan designation: Octreotide acetate Treatment of acromegaly, 05/08/2013 Withdrawn
Submitted by Anonymous (not verified) on 21 March 2025 - 10:32
Orphan designation: Octreotide acetate Treatment of acromegaly, 05/08/2013 Withdrawn
Human medicines European public assessment report (EPAR): Mycapssa, octreotide, Date of authorisation: 02/12/2022, Status: Withdrawn
Submitted by Anonymous (not verified) on 21 March 2025 - 10:30
Human medicines European public assessment report (EPAR): Mycapssa, octreotide, Date of authorisation: 02/12/2022, Status: Withdrawn